New data highlight cost-saving potential for Inpefa in HF

A new research paper concluding that the use of Inpefa (sotagliflozin) for the treatment of patients hospitalized for heart failure (HF) and suffering from co- morbid diabetes leads to significant positive impact on provider health system financial outcomes, largely due to bonus payments through alternative payment models (APM), according to US drug developer Lexicon Pharmaceuticals (Nasdaq: LXRX).

Researchers quantified the one-year financial impact on US provider health systems of adopting sotagliflozin relative to standard of care (SoC) across three common APMs, also known as value-based purchasing agreements: the Bundled Payments for Care Improvement-Advanced program (BPCI), Medicare Shared Savings Program for Accountable Care Organizations program (ACO), and the Hospital Readmissions Reduction Program (HRRP). HRRP is a Medicare value-based purchasing program designed to encourage hospitals to reduce the 30-day risk of unplanned readmissions for six procedures or conditions, including HF.

“Our analysis demonstrated that sotagliflozin use reduced the frequency of patient hospital readmissions and emergency department visits, leading providers to receive larger value-based bonus payments under these alternative payment models,” said Jason Shafrin, of the Center for Healthcare Economics and Policy at FTI Consulting, and the lead author of the research paper.